Zimbabwe has turned down a significant US health deal worth $367m (272 million pounds) spanning five years over Washington's insistence on sensitive information.
This move became public after a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson later clarified that the United States was requesting biological samples for research and commercial purposes while was not willing to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more dialogue to find a deal agreeable to both sides so the country's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a court suspended a similar deal with the US after legal challenges were filed about the security of Kenyans' medical information.
After resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his government was seeking direct bilateral deals to enhance openness and accountability.
According to statements, Sixteen nations in Africa have to date agreed to these new agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information indefinitely, without any equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that might result from that shared data," he stated.
"In essence, our nation would supply the raw materials for medical research without any certainty that the resulting innovations would be accessible to our population if a future disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining frameworks already established via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This system is intended to guarantee that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage continued discussions with our US partners on how future co-operation could be designed in a manner that respects the sovereignty and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but suggested that talks should continue given that much of the country's HIV programmes were funded by external financing.
"If specific concerns exist, such as those involving information security or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," the group said.
The situation emphasises the ongoing challenges between receiving vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.